China's Tesla Y Rivalling Xiaomi YU7, Bags Nearly 3 Lakh Orders In An Hour
Chinese electric vehicle maker Xiaomi received almost 300,000 pre-orders within an hour for its first sport utility vehicles in what the company said was a "miraculous" moment for the industry. Lei Jun, founder and CEO of the electronics-turned-car company, said he was astonished by the reaction from customers. "My goodness, in just two minutes, we received 196,000 paid pre-orders and 128,000 lock-in orders," Lei said in a video distributed after the vehicle's launch on Thursday night. "We may be witnessing a miracle in China's automotive industry."
The company's electric vehicle division said later on its official Weibo account that there had been 289,000 pre-orders for the five-seater YU7, priced from 253,500 yuan (about $35,000), within the first hour of sales.
Also Read - Rolls-Royce La Rose Noire Spotted Overseas; Here's What Makes It Unique
Xiaomi's Hong Kong-listed shares soared eight percent at one point before paring their gains but ending at a record high.
The Beijing-based commercial tech giant made its first foray into car-making with its SU7 EV model last year, part of a broader industry push to boost domestic consumption.
Initial enthusiasm for intelligent driving features in such vehicles was tempered by the fatal crash of a Xiaomi SU7 in March. The vehicle had been in assisted driving mode just before it crashed, killing three students.
Premier Li Qiang used the World Economic Forum in Tianjin this week to outline China's ambition to become a "major consumption powerhouse", emphasising policies to stimulate demand for high-value goods such as electric vehicles.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
3 hours ago
- The Hindu
Chennai Metrowater pilots robotic cleaning in sewage pumping stations to boost efficiency and workers' safety
After deploying robots to clean sewer lines in some city zones, Chennai Metrowater is now piloting the use of robotic technology in sewage pumping stations in Thiruvanmiyur. The initiative aims to enhance operational safety and efficiency by minimising manual intervention. The water agency has already added Bandicoot Mobility, a robot that cleans maintenance holes of the sewer network, to remove clogged waste in sewer lines in zone 6 ( 9 (Teynampet) and 13 (Adyar). With robotic devices, which were developed by Genrobotics, a Kerala-based startup, helping to reduce clogging of lines for a year now, the water agency is exploring other innovative technologies to improve maintenance of sewer infrastructure. Officials of the Metrowater said an advanced robot with remote control unit and cameras, Wilboar, is being used to clean the sewage wells in Thiruvanmiyur sewage pumping station on a pilot basis. The robotic unit developed by Genrobotics is lowered into the wells that have a depth of up to 10 metre to remove the silt. With high-pressure water jets and grinders, the device grinds accumulated sludge into finer particles and clears them. This would eliminate the challenges in the use of conventional processes, improve efficiency of cleaning sewer wells and reduce complaints of sewage overflow in the pipelines. The Thiruvanmiyur sewage pumping station has a capacity to handle 15 million litres of sewage a day. Such robotic devices are already in use at Nellore, Andhra Pradesh and Thiruvananthapuram, Kerala, said officials. There are 375 sewage pumping stations in the city. Such robotic devices would be deployed in sewer well cleaning operations in other pumping stations following the success of the trial implementation. Rao, president, Chennai Metropolitan Water Supply and Sewerage Board Labourers Union, said it was a welcome initiative to ensure workers' safety and reduce manual intervention. Such efforts must be expanded to densely populated urban spaces and monitored for regular maintenance. Workers hired for sewer network maintenance should be redeployed to other roles. Nearly 2,850 labourers have been hired for sewer and water network maintenance in Chennai.
Economic Times
3 hours ago
- Economic Times
Logistics played key role in Operation Sindoor success, says Rajnath Singh
Synopsis Defence Minister Rajnath Singh lauded Indian agencies for their seamless logistics management during Operation Sindoor, emphasizing its crucial role in the operation's success. He highlighted that modern warfare relies not only on weaponry but also on the timely delivery of resources. Seamless logistics management by Indian agencies-from mobilisation of the armed forces to delivering equipment at the right time and place-was a deciding factor in the success of Operation Sindoor, defence minister Rajnath Singh said on Sunday. ADVERTISEMENT In a virtual address at the convocation ceremony of Vadodara-based Gati Shakti Vishwavidyalaya (GSV), the minister said in the current era, wars are not just won by guns and bullets but by time-bound delivery of material, highlighting Op Sindoor as an example of excellent logistics management. "Whether it's soldiers fighting on the border or personnel engaged in disaster management, without coordination or proper management of resources, even the strongest of intentions weaken. Logistics is the power that transforms chaos into control. Power is measured not only by weapons, but also by timely resource management. Be it war, disaster or global pandemic, the nation which keeps its logistics chain strong is the most stable, secure and capable," he said. (You can now subscribe to our Economic Times WhatsApp channel) (Catch all the Business News, Breaking News, Budget 2025 Events and Latest News Updates on The Economic Times.) Subscribe to The Economic Times Prime and read the ET ePaper online. NEXT STORY
Economic Times
3 hours ago
- Economic Times
Cheaper cancer care therapy earns big bucks for pharma company
India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow challenges. ImmunoACT, in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 crore. Founded by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in 2018. ImmunoACT's NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October 2023. NexCAR19 was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in India. In CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion." Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla, Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts. Globally, CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.
